Clinical Trial End Points in Severe COVID-19.

Desai, Aakash; Kulkarni, Amit; Rajkumar, S Vincent; Gyawali, Bishal

Desai, Aakash; Kulkarni, Amit; Rajkumar, S Vincent; Gyawali, Bishal.

Desai A; Department of Medicine, University of Connecticut, Farmington. Electronic address: dr.aakashdesai@gmail.com.
Kulkarni A; Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis.
Rajkumar SV; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
Gyawali B; Department of Oncology, Queen's University, Kingston, Ontario, Canada; Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada; Division of Cancer Care and Epidemiology, Queen's University, Kingston, Ontario, Canada.

Mayo Clin Proc ; 95(8): 1578-1580, 2020 08.

Article in English | MEDLINE | ID: covidwho-701705

Subject(s)

Betacoronavirus; Clinical Trials as Topic/methods; Coronavirus Infections/therapy; Outcome Assessment, Health Care/methods; Pneumonia, Viral/therapy; Research Design; COVID-19; Coronavirus Infections/diagnosis; Coronavirus Infections/mortality; Humans; Pandemics; Pneumonia, Viral/diagnosis; Pneumonia, Viral/mortality; SARS-CoV-2; Severity of Illness Index

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Research Design / Clinical Trials as Topic / Outcome Assessment, Health Care / Coronavirus Infections / Betacoronavirus Type of study: Diagnostic study / Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Mayo Clin Proc Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google